Multi-omics reveal mechanisms of action of gut microbes and metabolites in infantile cholestatic hepatopathy

Technical Summary: Multi-omics Reveal Mechanisms of Action of Gut Microbes and Metabolites in Infantile Cholestatic Hepatopathy

Problem Statement
Infantile cholestatic hepatopathy (ICH) is a critical pediatric liver disorder characterized by bile flow obstruction, leading to liver damage, malnutrition, and growth delays. It remains a leading indication for pediatric liver transplantation. While the "gut-liver axis" is recognized as a key mediator in liver pathophysiology, the specific mechanisms linking gut microbiota dysbiosis to metabolic disturbances in ICH remain incompletely elucidated. Previous studies have established associations between microbiome alterations and liver diseases, but a comprehensive, integrated analysis of microbial composition and metabolic profiles specific to ICH is needed to identify pathophysiological mechanisms and potential therapeutic targets.

Methodology
This study employed an integrated dual-omics approach combining 16S rRNA gene sequencing and untargeted metabolomics to analyze fecal samples from 20 ICH-diagnosed infants and 20 healthy controls.

• Microbiome Analysis: Genomic DNA was extracted and subjected to 16S rRNA sequencing (Illumina NovaSeq PE250). Data processing involved quality filtering, chimera removal, and Amplicon Sequence Variant (ASV) generation using DADA2. Taxonomic annotation was performed against the SILVA database. Diversity was assessed via Alpha (Chao1, Shannon, Simpson) and Beta (Bray-Curtis, UniFrac) diversity metrics. Differential abundance was identified using LEfSe, and functional potential was predicted using PICRUSt2 against COG, GO, and KEGG databases.
• Metabolomics Analysis: Metabolites were extracted using 80% methanol and analyzed via LC-MS (TripleTOF 6600) in both positive and negative ionization modes. Data processing involved peak detection, alignment, and annotation using XCMS, CAMERA, and metaX. Differential metabolites were screened based on VIP > 1, P < 0.05, and fold-change > 1.2. Pathway enrichment was conducted using KEGG.
• Integrative Analysis: Spearman correlation analysis was performed to establish associations between differential gut microbes and differential metabolites. Key interactions were filtered using thresholds of |r| > 0.65 and P < 0.05.

Key Results

• Microbial Composition: While Alpha diversity indices showed no significant differences between groups, Beta diversity analysis (PCoA and NMDS) revealed distinct separation between the ICH and control microbiomes. At the taxonomic level, the ICH group exhibited a significant reduction in Actinobacteriota, Bifidobacteriaceae, and Bifidobacterium. Conversely, there was an enrichment of Enterobacteriaceae, Morganellaceae, and specific genera including Escherichia-Shigella, Streptococcus, Klebsiella, Veillonella, and Actinomyces.
• Metabolomic Profiles: The study identified 388 differential metabolites (278 upregulated, 110 downregulated). These metabolites were enriched in 53 significant pathways, with top pathways including glycerophospholipid metabolism, teichoic acid biosynthesis, and choline metabolism in cancer.
• Microbe-Metabolite Associations: Integrative correlation analysis identified 17 significant microbe-metabolite pairs. Nine specific metabolites were strongly linked to three key bacterial genera:
  • Veillonella was associated with Geosmin.
  • Actinomyces was associated with gamma-Decalactone, Verbenol, 2-Octenoic acid, (-)-alpha-Pinene, and Goshuyic acid.
  • Bifidobacterium was associated with cis-Muconic acid, 4-Acetylbutyrate, and trans-4-Coumaric acid.
• Functional Predictions: PICRUSt2 analysis suggested functional shifts in the ICH microbiome, including enrichment in N-acyltransferase activity and NAD salvage pathways.

Significance and Claims
The authors claim that this study provides novel insights into the pathophysiology of ICH by integrating multi-omics data to map specific correlations between gut microbiota dysbiosis and metabolic disturbances. The identification of nine metabolites associated with three key bacterial genera (Veillonella, Actinomyces, and Bifidobacterium) offers potential diagnostic indicators and therapeutic targets.

Specifically, the paper highlights the depletion of beneficial Bifidobacterium and the overgrowth of Veillonella and Actinomyces as central features of the disrupted gut-liver axis in ICH. The study notes that while Bifidobacterium is known for its protective role in bile acid metabolism and gut barrier integrity, Veillonella enrichment is linked to liver injury and bile acid metabolism alterations. Furthermore, the paper documents the first association between Actinomyces and specific metabolites like alpha-Pinene in the context of ICH, suggesting a potential, albeit unexplored, role in hepatoprotection or pathology.

The authors maintain a modest tone regarding clinical application, acknowledging that the findings are currently descriptive and limited by the technical constraints of 16S sequencing. They conclude that while these findings establish a theoretical framework for future interventions, large-scale cohort validation is required before clinical applicability can be confirmed.